Dose-Proportional Pharmacokinetics of Risedronate on Single-Dose Oral Administration to Healthy Volunteers

Journal of Clinical Pharmacology

Volumn 40, Issue 3, 2000, Pages 258-265

  Mitchell, David Y ^a,b   Eusebio, Rachelle A ^a   Sacco Gibson, Nancy A ^a   Pallone, Karen A ^a   Kelly, Sandra C ^a   Nesbitt, John D ^a   Brezovic, Christopher P ^a   Thompson, Gary A ^a   Powell, James H ^a  

^a PROCTER AND GAMBLE PHARMACEUTICALS   (United States)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG DERIVATIVE; ETIDRONIC ACID; RISEDRONIC ACID;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; HUMAN; MALE; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL;

ADMINISTRATION, ORAL; ADULT; DOSE-RESPONSE RELATIONSHIP, DRUG; ETIDRONIC ACID; FEMALE; HUMANS; MALE;

EID: 0034145470     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/00912700022008928     Document Type: Article

References (31)

1. Eastell R: Drug therapy: treatment of postmenopausal osteoporosis (review). N Engl J Med 1998;338:736-746.
2. Francis RM: Bisphosphonates in the treatment of osteoporosis in 1997: a review. Curr Ther Res 1997;58:656-678.
3. Adami S, Bhalla AK, Dorizzi R, Montesanti F, Rosini S, Salvagno G, Lo Cascio V: The acute-phase response after bisphosphonate administration. Calcif Tissue Int 1987;41:326-331.
4. Kellihan M, Mangino P: Pamidronate. Ann Pharmacother 1992;26: 1262-1269.
5. O'Doherty D, Gertz B, Tindale W, Sciberras D, Surviil T, Kanis J: Effects of five daily 1 h infusions of alendronate in Paget's disease of bone. J Bone Miner Res 1992;7:81-87.
6. Vasikaran S, Khan S, McClosky E, Kanis J: Sustained response to intravenous alendronate in postmenopausal osteoporosis. Bone 1995; 17:517-520.
7. Roux C, Ravaud P, Cohen-Solal M, de Vernejoul MC, Guillemant S, Cherruau B, et al: Biologic, histologic and densitometric effects of oral risedronate on bone in patients with multiple myeloma. Bone 1994;15:41-49.
8. Hosking DJ, Eusebio RA, Chines AA: Paget's disease of bone: reduction of disease activity with oral risedronate. Bone 1998;22: 51-55.
9. Patel S, Pearson D, Bhallah A, Maslanka W, White DA, Hosking DJ: Changes in bone mineral density in patients with Paget's disease treated with risedronate. Ann Rheum Dis 1997;56:405-409.
10. Delmas PD, Balena R, Confravreux E, Hardouin C, Hardy P, Bremond A: Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a double-blind, placebo-controlled study. J Clin Oncol 1997;15:955-962.
11. McClung MR, Bensen W, Bolognese MA, Bonnick SL, Ettinger MP, Harris ST, et al: Risedronate increases BMD at the hip, spine and radius in postmenopausal women with low bone mass. J Bone Miner Res 1997;12:S169.
12. Mitchell DY, Barr WH, Eusebio RA, Pallone KA, Duke FP, Russell DA, et al: Determination of intravenous pharmacokinetics, absolute and relative bioavailability, and intra- and inter- subject variability of risedronate using a four period replicate study design. Pharm Res 1997;14:S610.
13. Fitton A, McTavish D: Pamidronate: a review of its pharmacological properties and therapeutic efficacy in resorptive bone disease. Drugs 1991;41:289-318.
14. Fogelman I, Smith L, Mazess R, Wilson MA, Bevan JA: Absorption of oral diphosphonate in normal subjects. Clin Endocrinol 1986;24:57-62.
15. Gertz BJ, Holland SD, Kline WF, Matuszewski BK, Freeman A, Quan H, et al: Studies of the oral bioavailability of alendronate. Clin Phamacol Ther 1995;58:288-298.
16. Mitchell DY, Eusebio RA, Dunlap LE, Pallone KA, Nesbitt JD, Russell DA, et al: Risedronate gastrointestinal absorption is independent of site and rate of administration. Pharm Res 1998;15:228-232.
17. Mitchell DY, Eusebio R, Pallone K, Clay M, Russell D, Thompson G: Bisphosphonate pharmacokinetics: use of simultaneous modelling of urine and serum data to determine parameters. Clin Pharmacol Ther 1997;61:155.
18. Mitchell DY, Eusebio RA, Axelrod DW, Hicks KR, Russell DA, Kamra LC, Powell JH: Risedronate pharmacokinetics following single and multiple dose intravenous administration. Bone 1997;20: 100S.
19. DeSilva BS, Whitham DJ, Bhullar B, Kamra LC, DeStefano AJ: Validation of an enzyme linked immunosorbent assay for the determination of risedronate in human serum. PharmSci 1998;1:S26.
20. Bernareggi A, Danese A, Cometti A, Buniva G, Rowland M: Pharmacokinetics of individual components of teicoplanin in man. J Pharmacokinet Biopharm 1990;18:525-543.
21. Statistical Consultants, Inc.: PCNONLIN and NONLIN84: software for the statistical analysis of nonlinear models. Amer Stat 1986;40:52.
22. Boxenbaum HG, Riegelman S, Elashoff RM: Statistical estimations in pharmacokinetics. J Pharmacokinet Biopharm 1974;2:123-148.
23. Gibaldi M, Perrier D: Pharmacokinetics. 2nd ed. New York: Marcel Dekker, 1982.
24. Wagner JG: Linear pharmacokinetic equations allowing direct calculations of many needed pharmacokinetic parameters from the coefficients and exponents of polyexponential equations which have been fitted to the data. J Pharmacokinet Biopharm 1976;4:443-467.
25. Gough K, Hutchison M, Keene O, Byrom B: Assessment of dose proportionality: Report from the Statisticians in the Pharmaceutical Industry/Pharmacokinetics UK Joint Working Party. Drug Info J 1995;29:1039-1048.
26. Hyldstrup L, Flesch G, Hauffe SA: Pharmacokinetic evaluation of pamidronate after oral administration: a study on dose proportionality, absolute bioavailability, and effect of repeated administration, Calcif Tissue Int 1993;53:297-300.
27. Sansom LN, Necciari J, Thiercelin JF: Human pharmacokinetics of tiludronate. Bone 1995;17:479S-483S.
28. Ylitato P, Holli K, Mönkkönen J, Juhakoski A, Linkko-Sippi S, Elo HA, Hanhijärvi H: Pharmacokinetics of increasing doses of clodronate (dichloromethyl bisphosphonate) in man. Paper presented at the Fifth World Conference on Clinical Pharmacology and Therapeutics 1992, Yokohama, Japan.
29. Fleisch H: The use of bisphosphonates in osteoporosis. Br J Clin Pract 1994;48:323-326.
30. O'Doherty DP, Bickerstaff DR, McCloskey EV, Hamdy NA, Beneton MN, Harris S, et al: Treatment of Paget's disease of bone with aminohydroxybutylidene bisphosphonate. J Bone Miner Res 1990;5: 483-491.
31. Zysset E, Ammann P, Jenzer A, Gertz B, Portmann L, Rizzoli R, et al: Comparison of a rapid (2-hr) versus a slow (24-hr) infusion of alendronate in the treatment of hypercalcemia of malignancy. Bone Miner 1992,18:237-249.